OSTEOPOROSIS

CAPITULO 17
combination therapy on the rate of bone loss after discontinuation of treatment ofpostmenopausal
osteoporosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002;137:875-83
7. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett- Connor E, Musliner TA, Palermo
L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ, Fracture Intervention Trial
Research Group. Effect of alendronate on risk of fracture in women with low bone density but without
vertebral fractures: results from the fracture intervention trial. JAMA 1998; 280:2077–82
8. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut 3rd CH, Brown J, Eriksen
EF, Hoseyni MS, Axelrod DW, Miller PD, for the VERT Study Group. Effects of risedronate treatment on
vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled
trial. JAMA 1999;282:1344 –52
9. Reginster J, Minne HW, Sorensen OH, Hooper M, Roux C, Brandi ML, Lund B, Ethgen D, Pack S,
Roumagnac I, Eastell R, on behalf of the Vertebral Efficacy with Risedronate Therapy (VERT) Study
Group. Randomized trial of the effects of risedronate on vertebral fractures in women with established
postmenopausal osteoporosis. Osteoporos Int 2000;11:83–91
10. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T,
Eastell R, Meunier PJ, Reginster JY, for the Hip Intervention Program (HIP) Study Group 2001. Effect of
risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333–40
11. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA,Cosman F, Lakatos P, LeungPC, Man Z,
Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer
D, Eriksen EF, Cummings SR, for the HORIZON Pivotal Fracture Trial Once-yearly zoledronic acid for
treatment ofosteoporosis. N Engl J Med 2007;356:1809–22
12. Adami S, Bhalla AK, DorizziR, Montesanti F, Rosini S, Salvagno G, Lo Cascio V. The acute phase response
after bisphosphonate administration. Calcif Tissue Int 1987; 41:326–31
13. Maalouf NM, Heller HJ, Odvina CV, Kim PJ, Sakhaee K. Bisphosphonate-induced hypocalcemia: report of
3 cases and review of literature. Endocr Pract 2006; 12:48–53
14. Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE. Safety and efficacy of risedronate in
patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled
analysis of nine clinical trials. J Bone Miner Res 2005;20:2105–15
15. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a
growing epidemic. J Oral Maxillofac Surg 2003;61:1115–17 (Letter)
16. Woo SB, Hellstein JW, Kalmar JR. Systematic review: bisphos- phonates and osteonecrosis of the jaws.
Ann Intern Med 2006;144:753–61
17. Bilezikian JP. Osteonecrosis of the jaw: do bisphosphonates pose a risk? N Engl J Med 2006;355:2278 –81
18. Black DM, Boonen S, Cauley J, Delmas P, Eastell R, Reid I, Rosario-Jansen T, Caminis J, Zhang J, Hu
H, Cummings S. Effect of once-yearly infusion of zoledronic acid 5 mg on spine hip fracture reduction in
postmenopausal women with osteoporosis: the HORIZON pivotal fracture trial. J Bone Miner Res 2006;
21(Suppl 1):S16
19. American Association of Oral and Maxillofacial Surgeons. Position paper on bisphosphonate- related
osteonecrosis of the jaws. J Oral Maxillofac Surg 2007;65:369–76
20. Update of safety review follow-up to the October1, 2007, Early communication about the ongoing safety
review of bisphosphonates (http:// www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationfor
PatientsandProvidersDrugSafetyInformationforHeathcareProfessionals/ucm136201.htm
21. Abraham SC, Cruz-Correa M, Lee LA, Yardley JH, Wu TT. Alendronate- associated esophageal injury:
pathologic and endoscopic features. Mod Pathol 1999;12:1152–57
22. Wysowski DK, Chang JT. Alendronate and risedronate: reports of severe bone, joint, and muscle pain. Arch
Intern Med 2005;165: 346 –47
23. Recker RR, Lewiecki EM, Miller PD, Reiffel J. Safety of bisphosphonates in the treatment of osteoporosis.
Am J Med 2009;122: S22–S32
24. Khosla S, Bilezikian JP, David W. Dempster DW, et al. Special Features: Position Statement: Benefits and
Risks of Bisphosphonate Therapy for Osteoporosis. JCEM 2012; 97: 2272-82
25. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR,
Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKier- nan F,
McKinney R, Nieves J, O’Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M.
Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for
Bone and Mineral Research. J Bone Miner Res 2010;25:2267–94
26. Bonnick SL. Going on a drug holiday? J Clin Densitom 2011;14: 377–83
27. Schwartz AV, Bauer DC, Cummings SR, Cauley JA, Ensrud KE, Palermo L, Wallace RB, Hochberg MC,
Feldstein AC, Lombardi A, Black DM. Efficacy of continued alendronate for fractures in women with and
without prevalent vertebral fracture; The FLEX trial. J Bone Miner Res 2010;25:976 –82
28. Black DM, Reid IR, Boonen S, Bucci-Rechtweg C, Cauley JA, Cos- man F, Cummings SR, Hue TF, Lippuner
210
OSTEOPOROSIS 2015